literature—captured?

Submission timeliness: Were reports submitted according to regulatory timelines?

Format and structure: Is the PSUR aligned with ICH E2C(R2) and local expectations?

Refer to Pharma SOP templates to benchmark your audit criteria.

Building an Effective PSUR Audit Checklist

An audit checklist helps ensure consistency and thoroughness. Sample items include:

• Does the PSUR include all required sections as per ICH guidance?
• Have all applicable products and markets been included in the submission?
• Are signal evaluations supported by sufficient data and justification?
• Is the benefit-risk section internally consistent with safety findings?
• Are timelines tracked and documented with justification for delays, if any?
• Was QA review documented and archived?

Customizing your checklist for specific regional requirements is advised. For instance, USFDA submissions may be integrated into PADERs, while TGA may demand region-specific addenda.

Tracking PSUR Compliance: Metrics and Tools

Compliance tracking involves monitoring key performance indicators (KPIs) related to PSUR submissions. Common metrics include:

• On-time submission rate (%)
• Number of audit findings per report
• Signal evaluation turnaround time
• Review cycle duration from data lock point (DLP) to final approval
• CAPA (Corrective and Preventive Actions) closure timelines

Use of digital dashboards and compliance management systems helps in visualizing these metrics across products and geographies. Validation of these systems is recommended under computer system validation protocols.

Implementing a PSUR Compliance Tracker

A PSUR tracker can be maintained in Excel or in a pharmacovigilance tool. Essential fields include:

1. Product name and active substance
2. Country or region of submission
3. DLP and reporting frequency (e.g., biannual, annual)
4. Submission due date and actual submission date
5. Health authority acknowledgment or feedback
6. CAPAs and responsible owner

This tracker should be updated in real-time and shared with cross-functional stakeholders including regulatory affairs and QA.

Common Audit Findings in PSURs

Some frequently observed audit findings include:

• Omissions in cumulative safety data
• Incorrect DLPs leading to misaligned timelines
• Incomplete signal assessment narratives
• Unjustified deviations from submission SOPs
• Delayed CAPA implementation

These issues often stem from unclear ownership, inadequate training, or lack of harmonized templates. Address these through documented training programs and standardized templates sourced from GMP SOP guidelines.

Preparing for Regulatory Inspections

During inspections, agencies may request:

• Full PSUR dossiers and revision history
• Evidence of signal evaluation and benefit-risk reasoning
• Audit reports and CAPA records
• Compliance metrics dashboards
• Submission confirmations or acknowledgment letters

Ensure all these documents are stored securely and readily accessible. Many companies use stability data systems that integrate with PSUR generation workflows.

Best Practices for PSUR Audit Readiness

• Schedule periodic internal audits annually
• Include cross-functional auditors to widen perspective
• Automate timeline tracking and alerts
• Link PSUR reviews to risk management plans (RMPs)
• Use mock inspections to assess readiness

Conclusion

Auditing PSUR submissions and tracking compliance are non-negotiable aspects of a mature pharmacovigilance system. With increasing scrutiny from global health authorities, pharmaceutical companies must adopt proactive strategies to ensure their PSUR processes are transparent, robust, and inspection-ready. Implementing audit checklists, using trackers, and deploying validation-backed systems ensures compliance—and more importantly—enhances patient safety and product lifecycle integrity.